Inhaled corticosteroids and chronic obstructive pulmonary disease: New and improved evidence?

American Journal of Respiratory and Critical Care Medicine

Volumn 172, Issue 4, 2005, Pages 407-408

  Samet, Jonathan M ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID;

CHRONIC LUNG DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORTICOSTEROID THERAPY; EDITORIAL; FOLLOW UP; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; PRIORITY JOURNAL; STEROID THERAPY; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; BRONCHODILATOR AGENTS; CASE-CONTROL STUDIES; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 23644436376     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.2506002     Document Type: Editorial

References (16)

1. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004;364:709-721.
2. Man SF. Sin DD. Inhaled corticosteroids in chronic obstructive pulmonary disease: is there a clinical benefit? Drugs 2005;65:579-591.
3. Sin DD, McAlister FA, Man SF, Anthonisen NR. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA 2003;290:2301-2312.
4. Highland KB, Strange C, Heffner JE. Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease: a meta-analysis. Ann Intern Med 2003;138:969-973.
5. Suissa S. Effectiveness of inhaled corticosteroids in COPD: bias in observational studies. Am J Respir Crit Care Med 2003;168:49-53.
6. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997;127:757-763.
7. Kiri VA, Pride NB, Soriano JB, Vestbo J. Inhaled corticosteroids in COPD: results from two observational designs free of immortal time bias. Am J Resp Crit Care Med 2005;172:460-464.
8. Garcia Rodriguez LA, Perez GS. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 1998;45:419-425.
9. Hansell A, Hollowell J, Nichols T, McNiece R, Strachan D. Use of the General Practice Research Database (GPRD) for respiratory epidemiology: a comparison with the 4th Morbidity Survey in General Practice (MSGP4). Thorax 1999;54:413-419.
10. Suissa S. Inhaled steroids and mortality in COPD: bias from unaccounted immortal time. Eur Respir J 2004;23:391-395.
11. Soriano JB, Maier WC, Visick G, Pride NB. Validation of general practitioner-diagnosed COPD in the UK General Practice Research Database. Eur J Epidemiol 2001;17:1075-1080.
12. Fan VS, Bryson CL, Curtis JR, Fihn SD, Bridevaux PO, McDonell MB, Au DH. Inhaled corticosteroids in chronic obstructive pulmonary disease and risk of death and hospitalization: time-dependent analysis. Am J Respir Crit Care Med 2003;168:1488-1494.
13. Samet JM. Measuring the effectiveness of inhaled corticosteroids for COPD is not easy! Am J Respir Crit Care Med 2003;168:1-2.
14. Rennard SI. Treatment of stable chronic obstructive pulmonary disease. Lancet 2004;364:791-802.
15. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-946.
16. Sin DD, Wu L, Anderson JA, Anthonisen NR, Buist S, Burge PS, Calverley PM, Connett JE, Lindmark B, Pauwels RA, et al. Inhaled corticosteroids and mortality in COPD. American Thoracic Society Mini-Symposium 2005, San Diego, CA. Abstract page A890.